CPT® Code 81443

Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)

The CPT® Code 81443 pertains to genetic testing specifically designed for the identification of severe inherited conditions. This testing utilizes a genomic sequence analysis panel that must include the sequencing of at least 15 genes. Among the conditions that can be identified through this testing are cystic fibrosis and various disorders associated with Ashkenazi Jewish ancestry, such as Bloom syndrome, Canavan disease, and Gaucher disease, among others. The genetic panel encompasses a range of genes, including but not limited to ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, and PAH. Genomic sequencing is a critical process that determines the precise order of amino acids, or bases, that constitute DNA molecules. This analysis examines all coding exons of the genes included in the panel, allowing for the detection of various genetic mutations, including deletion/duplication mutations, insertion mutations, single nucleotide polymorphisms (SNPs), structural variations (SV), and copy number variations (CNVs). The application of genomic panel testing is significant in clinical settings, as it may be indicated for confirming a clinical diagnosis, identifying at-risk family members, and determining carrier status during prenatal assessments. This comprehensive approach to genetic testing plays a vital role in the early detection and management of severe inherited conditions.